Are you Dr. Stanford?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 63 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
244 5th Ave
# 9B
New York, NY 10001Phone+1 212-684-3780
Summary
- Dr. Arielle Stanford, MD is a board certified psychiatrist in New York, New York. She is currently licensed to practice medicine in New York and Massachusetts.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Psychiatry, 1999 - 2003
Washington University in St. Louis School of MedicineClass of 1999
Certifications & Licensure
NY State Medical License 2000 - 2026
MA State Medical License 2011 - 2016- American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS) Start of enrollment: 2004 Sep 01
Publications & Presentations
PubMed
- 18 citationsBuprenorphine/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3).John Zajecka, Arielle D. Stanford, Asli Memisoglu, William F. Martin, Sanjeev Pathak
Neuropsychiatric Disease and Treatment. 2019-04-04 - 48 citationsOpioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies.Maurizio Fava, Michael E. Thase, Madhukar H. Trivedi, Elliot Ehrich, William F. Martin
Molecular Psychiatry. 2020-07-01 - 1 citationsEnsuring Stakeholder Feedback in the Design and Conduct of Clinical Trials for Rare Diseases: ISCTM Position Paper of the Orphan Disease Working Group.Gahan J Pandina, Joan Busner, Lucas Kempf, Joan Fallon, Larry D Alphs
Innovations in Clinical Neuroscience. 2024-03-01
Authored Content
- S99. Evaluation of Abuse Potential of Samidorphan in Healthy, Nondependent, Recreational Opioid UsersApril 2018
- S99. Evaluation of Abuse Potential of Samidorphan in Healthy, Nondependent, Recreational Opioid UsersApril 2018
Grant Support
- Negative Symptoms Of Schizophrenia: From Phenomenology To Targeted TreatmentNational Institute Of Mental Health2011
- Negative Symptoms Of Schizophrenia: From Phenomenology To Targeted TreatmentNational Institute Of Mental Health2007–2011
